RVMD Earnings & Financial Statements
Revolution Medicines, Inc.
$189.26
-$4.26(-2.20%)
35
Overall
40
Value
30
Tech
36
Quality
Market Cap
$41.48B
Volume
1.57M
52W Range
$47.45 - $224.31
Target Price
$253.00
RVMD earnings and financial statements: Revolution Medicines, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RVMD Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $561.0K | $11.58M | $35.38M | $29.39M |
| Operating income | -$1.18B | -$689.52M | -$487.19M | -$258.28M | -$188.01M |
| EBITDA | -$1.09B | -$589.02M | -$430.58M | -$239.47M | -$179.75M |
| Net income | -$1.13B | -$600.09M | -$436.37M | -$248.71M | -$187.09M |
| EPS (diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $2.35B | $2.56B | $2.06B | $811.93M | $737.99M |
| Total liabilities | $723.21M | $293.10M | $235.51M | $126.74M | $135.42M |
| Shareholders’ equity | $1.63B | $2.27B | $1.83B | $685.19M | $602.57M |
| Cash and equivalents | $383.75M | $543.06M | $696.15M | $161.41M | $108.50M |
| Long-term debt | $142.23M | $122.97M | $80.58M | $57.43M | $60.42M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$897.74M | -$557.44M | -$350.57M | -$224.40M | -$147.18M |
| Capital expenditure | -$15.99M | -$10.31M | -$7.73M | -$10.82M | -$6.53M |
| Free cash flow | -$913.73M | -$567.74M | -$358.30M | -$235.22M | -$153.71M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RVMD | $189.26 | -2.2% | 1.57M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Revolution Medicines, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW